AIM Vaccine (HKG:6660) received the US Food and Drug Administration approval for clinical trials of its mRNA herpes zoster vaccine, according to a Sunday filing with the Hong Kong bourse.
Preclinical studies demonstrated that AIM's vaccine immune response significantly outperformed that of existing commercial recombinant subunit vaccines.
The drugmaker's shares were up by almost 8% in recent trade on Monday.